Troriluzole in Adult Subjects With Spinocerebellar Ataxia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03701399|
Recruitment Status : Active, not recruiting
First Posted : October 10, 2018
Last Update Posted : January 20, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Spinocerebellar Ataxias Spinocerebellar Ataxia Type 1 Spinocerebellar Ataxia Type 2 Spinocerebellar Ataxia Type 3 Spinocerebellar Ataxia Type 6 Spinocerebellar Ataxia Type 7 Spinocerebellar Ataxia Type 8 Spinocerebellar Ataxia Type 10||Drug: troriluzole Drug: Placebos||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||218 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects With Spinocerebellar Ataxia.|
|Actual Study Start Date :||March 8, 2019|
|Actual Primary Completion Date :||February 18, 2022|
|Estimated Study Completion Date :||December 22, 2024|
Experimental: Arm 1: BHV-4157
Troriluzole 200mg by mouth
200 mg by mouth
Placebo Comparator: Arm 2: Placebo
Placebo 200mg by mouth
200 mg by mouth
- Change from Baseline in the total score of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) after 48 weeks of treatment. [ Time Frame: Baseline to week 48 ]An increase in the total score indicates a worsening of symptoms.
- 1. Change from baseline in Patient Impression of Function and Activities of Daily Living Scale (PIFAS) score at Randomization Phase Week 48 [ Time Frame: Baseline to week 48 ]An increase in the total score indicates a worsening of symptoms.
- Change from baseline in Activities of Daily Living Scale from the Friedreich's Ataxia Rating Scale (FARS-ADL) at Randomization Week 48. [ Time Frame: Baseline to week 48 ]An increase in the total score indicates a worsening of symptoms.
- Change from baseline in Functional Staging for Ataxia from the Friedreich's Ataxia Rating Scale (FARS-FUNC) at Randomization Phase Week 48 [ Time Frame: Baseline to week 48 ]An increase in the total score indicates a worsening of symptoms.
- 4. Frequency of subjects with the following adverse events (AEs) identified from case report forms: AEs (by severity; by relationship to study drug; overall); SAEs; and AEs leading to treatment discontinuation. [ Time Frame: Baseline to week 48 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Subjects with a known or suspected diagnosis of the following specific hereditary ataxias: SCA1, SCA2, SCA3, SCA6, SCA7, SCA8 and SCA10; currently only enrolling SCA 1, SCA2, SCA3, SCA7, and SCA10 (the cap has been met for SCA6 and SCA8 (on May 31, 2019));
- A subject should have a confirmed genotypic diagnosis from a CLIA certified lab (can produce test results); or,
- A subject has a family member that has a confirmed genotypic diagnosis from a CLIA certified lab (can produce test results) and must be willing to undergo genetic testing to confirm underlying SCA diagnosis; or,
- A subject has a confirmed genotypic diagnosis from a lab that is not CLIA certified and must be willing to undergo genetic testing to confirm underlying SCA diagnosis; or,
- A subject has clinical evidence that supports diagnosis of one of the aforementioned SCA genotypes but does not have producible test results from a CLIA certified lab from either a family member or for his or herself and the subject must be willing to undergo such testing to confirm the SCA diagnosis (in this case, site must wait for results of genotypic testing prior to randomization)
- Ability to ambulate 8 meters without human assistance (canes and other devices allowed)
- Screening f-SARA total score ≥3;
- Score of ≥1 on gait subsection of the f-SARA
- Determined by the investigator to be medically stable at Baseline/randomization as assessed by medical history, physical examination, laboratory test results, and electrocardiogram testing.
- A ≥ 2-point difference on the Modified Functional SARA score between screening and baseline
- MMSE score <24
- Any medical condition other than one of the hereditary ataxias specified in the inclusion criteria that could predominantly explain or contribute significantly to the subjects' symptoms of ataxia.
- A prominent spasticity or dystonia that, in the opinion of the investigator, will compromise the ability of the SARA instrument to assess underlying ataxia severity.
- A score of 4 on any individual item (Items 1-4) of the f-SARA
- Subjects should be excluded at screening or baseline if medical conditions have arisen or there is a change in disease status that could confound the ability of the SARA to accurately reflect changes in ataxia severity.
- Active liver disease or a history of hepatic intolerance to medications that in the investigator's judgment, is medically significant
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03701399
|Responsible Party:||Biohaven Pharmaceuticals, Inc.|
|Other Study ID Numbers:||
|First Posted:||October 10, 2018 Key Record Dates|
|Last Update Posted:||January 20, 2023|
|Last Verified:||January 2023|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Ataxia, SCA, Spinocerebellar Ataxia
Nervous System Diseases
Central Nervous System Diseases
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn